AN OPPORTUNITY FOR DOCTORS AND HEALTHCARE ORGANIZATIONS
Up to 34% of asymptomatic patients 45 years or older carry confirmed functional and/or structural abnormalities that are at risk of developing into heart failure if untreated. At this stage, symptoms are often non-specific, shortness of breath and faintness are among the chief complaints for patients to visit urgent care centers.
The often mild and non-specific symptoms can be misdiagnosed easily even by experienced staff, especially when patients report no previous cardiac morbidity, are outside of “traditional” risk groups or have comorbidities that display similar symptoms. A worryingly high number of patients are thus discharged without cardiac workup and sent home without referral to a cardiology specialists.
These patients are at great risk to enter acute heart failure and require emergency hospitalization and surgical and pharmaceutical intervention.
Left ventricular dysfunction is associated with a substantial risk for heart failure indicating an imperative to develop effective intervention at these stages.J Am Coll Cardiol HF 2016;4:237–48
In asymptomatic patients however, developing structural and functional changes to the heart can not readily be seen using these methods. To-date, only transthoracic echocardiography can generate a detailed view of the heart but its acquisition and operational costs are prohibitive to the screening environment.
HEMOTAG CARDIOPULMONARY ASSESSMENT
Hemotag offers to solve this issue by giving the care team the tools necessary to discover heart disease before clinical symptoms become manifest.
- The procedure is simple and fast
- Generates concise data within 5 minutes
- Does not affect workflow
- Can be operated by any healthcare professional